Europe’s CHMP Okays Samsung’s Infliximab Biosimilar
This article was originally published in PharmAsia News
Executive Summary
Samsung Bioepis' infliximab biosimilar, Flixabi, has won a green light from the European Medicines Agency's CHMP for a broad range of indications, marking another step forward for the South Korean firm’s international ambitions.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.